Skip to main content
ABUS logo

ABUS

Arbutus Biopharma Corporation

$4.03

1.11%

Trade Ideas Performance

Latest Closed Trade Idea

$4.03

1.11%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

13

Social

10

About

Events of Arbutus Biopharma Corporation (ABUS)

In October 2026, the FDA clinical hold on the Investigational New Drug (IND) application for AB-101 was lifted, and Arbutus announced the final results of its US$230 million modified "Dutch Auction" tender offer. In August 2026, the company commenced a US$230 million modified "Dutch Auction" tender offer to repurchase common shares, returning proceeds from a recent settlement with Moderna, and also reported its Second Quarter 2026 financial results. In July 2026, Arbutus filed additional patent infringement suits against Pfizer and BioNTech and received approximately $178 million from Moderna as part of a patent litigation settlement. In May 2026, the company reported its First Quarter 2026 financial results, which included details of the Moderna settlement where Arbutus expected to receive an estimated $178.7 million. In April 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to imdusiran for chronic hepatitis B.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)